The FGFR inhibitors erdafitinib (NCT03238196) and TAS-120 (NCT04024436) have entered clinical trials in combination with fulvestrant to treat ER+ breast cancer with FGF amplification. This evidence concerns the gene ESR1 and breast carcinoma.